The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Evaluating the role of systemic therapies in SCLC
Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of systemic therapies in treating patients with small cell lung cancer (SCLC). As patients with SCLC are typically diagnosed in the advanced stages, surgery is no longer viable due to metastasis. Most patients will respond to systemic therapies such as chemotherapy and immunotherapy, but recurrence can occur in a number of patients, especially when the disease has metastasized. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
